Consultation on Draft Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINS)

The purpose of this consultation is to seek feedback from stakeholders on the Draft Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINs). This document is intended to consolidate currently published information to improve accessibility of information and understanding of regulatory requirements for industry.

Join in: how to participate

Send an email to hc.DIN.sc@canada.ca with your ideas or comments to make yourself heard.

Who is the focus of this consultation

We will engage with:

• Industry stakeholders, including: Disinfectants, Generic Drugs, Innovators / Biologic Drugs, Over-the-Counter (Non-prescription Drugs), Radiopharmaceutical Drugs and Veterinary Drugs
• Interested members of the public and consumers

Key questions for discussion

Your ideas and inputs are sought around the following themes/topics:

• What are your thoughts on the consolidation of information into one guidance document?
• What other information on the processes would be valuable from industry's point of view? Please identify specific areas that could be better covered.

The input gathered through this process will be used to publish a final guidance document for implementation.

Contact us

Via email: HC.DIN.SC@canada.ca